Back

The Drug-Induced Respiratory Disease Website and App

Bortezomib

Pulmonary complications from bortezomib are unusual in the West and have been mainly described in Japan and Asia. The respective role of ethnicity, case definition and other confounding factors cannot be assessed at the present time

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I - Interstitial/parenchymal lung disease

I.a

Pneumonitis (ILD), acute and/or severe (may produce the ARDS pattern)
I.b

Pneumonitis (interstitial lung disease/ILD)
I.d

Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.l

Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

II - Pulmonary edema - Acute lung injury - ARDS

II.b

ARDS - Acute lung injury

III - Pulmonary/alveolar/airway hemorrhage/bleeding

III.a

Alveolar hemorrhage (AH), diffuse AH (DAH)

VI - Pulmonary vasculopathy

VI.b

Pulmonary arterial hypertension

X - Systemic/Distant conditions, syndromes and reactions

X.c

Capillary leak syndrome (CLS)
X.n

Tumor lysis syndrome (TLS)
X.o

Neutrophilic dermatosis (Pyoderma, Sweet syndrome)

XII - Cardiovascular involvement / toxicity

XII.a

Left or biventricular dysfunction/failure
XII.d

Myocarditis (can be fulminant)
XII.f

Cardiomyopathy (acute, subacute, chronic)
XII.q

Pericarditis (see also under XIIc)
XII.s

Heart block (bundle branch- or AV-)
XII.ai

Cardiotoxicity

XV - Pathology

XV.a

Path: NSIP-cellular pattern (see also Ia, Ib)
XV.c

Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XVII - Infections & related conditions

XVII.e

Pneumocystis jiroveci pneumonia
XVII.h

Nontuberculous pulmonary mycobacterial infection/superinfection
XVII.j

Mucormycosis (pulmonary, tracheobronchial or systemic)